Rx/Dx Companion Products, Not New Labels, Will Inspire Physicians to Use Genetic Tests | GenomeWeb
This story has been updated to add a sentence that stresses that the FDA does not plan to do away with label changes when it comes to recommending the use of diagnostics. Rather, it will update labels when it deems it necessary.
Simultaneously developing and marketing targeted drugs with companion diagnostics may be the best way to encourage physicians to incorporate genetic testing in their clinical care, according to a US Food and Drug Administration official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.